Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company has entered into a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that this cooperation provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The agreement is seen as fair and reasonable, aligning with the overall interests of the company and its shareholders [1] Group 2: Objectives and Framework - The cooperation aims to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] - The project-driven model will focus on resource sharing and efficient communication, allowing the company to utilize the advanced laboratory facilities, animal supply resources, and valuable data assets of the Sun Yat-sen University Hong Kong Advanced Institute [1] - This strategic partnership is expected to create a mutually beneficial framework that supports growth and ensures long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]
港股异动 | 中国抗体-B(03681)盘中涨超11% 公司与中山大学香港高等研究院就生物医药创新研发等达成合作